Cooperation with Takeda saves Ascentage from survival problem, but self-building sales team remains a challenge. Investors eye anther deal with MNC. Short-term market value target is 50% that of HCM.
What is covered in the Full Insight:
Ascentage Pharma's partnership with Takeda
Consequence of the partnership for Ascentage's financial status
Future prospects of Ascentage's product olverembatinib
Investors' inquiry about additional pipeline candidates
Concern over Ascentage's capacity to commercialize on its own
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.